Develops and commercializes enzyme-based medical devices and products for enteral nutrition, addressing fat malabsorption and nutritional challenges associated with gastrointestinal disorders and rare diseases
Develops and commercializes enzyme-based medical devices and products for enteral nutrition, addressing fat malabsorption and nutritional challenges associated with gastrointestinal disorders and rare diseases. Its lead product, RELiZORB, uses immobilized lipase to hydrolyze fats in enteral feeding formulas and improve fat absorption, including in patients with cystic fibrosis and other serious conditions.